Shandong Suncadia Medicine Co., Ltd. Drug Pipeline

Shandong Suncadia Medicine Co., Ltd. maintains a substantial clinical development portfolio, with 63 trials registered since 2008, of which 38 are currently active. The pipeline spans early- to late-stage development, with 18 active Phase 1 trials, 18 active Phase 2 trials, and 10 active Phase 3 trials across seven therapeutic areas. The portfolio demonstrates a strong concentration in oncology, which accounts for 37% of active programs (14 trials). Within oncology, the leading indication is breast cancer, with 10 active trials, including 3 in Phase 3. The next-largest therapeutic areas are cardiovascular (7 active trials) and metabolic disorders (6 active trials). The remaining active trials are distributed across pain (2 trials), renal (1 trial), and musculoskeletal (1 trial) indications. Beyond breast cancer, the most-studied oncology indication is advanced solid tumors, with 4 active trials. The relatively high number of Phase 3 trials suggests potential near-term catalysts.